Search - tctmd.com

Displaying 21 - 40 of 136

Sort: Relevancy | Date

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

November 13, 2023

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

News Conference News AHA 2023

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

November 12, 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

News Conference News AHA 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Michael O'Riordan

November 12, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

November 11, 2023

RADIANCE Modest Renal Denervation Effect Remains at 6 Months

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

October 31, 2023

Renal Denervation: Exploring Its Potential Beyond Hypertension

News Conference News EuroPCR 2023

Renal Denervation: Exploring Its Potential Beyond Hypertension

May 18, 2023

Two New Renal Denervation Systems Look Good in Uncontrolled BP

News Conference News EuroPCR 2023

Two New Renal Denervation Systems Look Good in Uncontrolled BP

May 17, 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

March 08, 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

March 08, 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

Sizeable Minority of Pregnant Women Have CVD, US Data Show

News Conference News AHA 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

November 11, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

China Rural Intervention Still Reaping BP Control Wins at 3 Years

News Conference News AHA 2022

China Rural Intervention Still Reaping BP Control Wins at 3 Years

November 09, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.